FDA Approves Strensiq for Alexion Pharma (ALXN); Oppenheimer Reiterates Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Baird Remains Bullish on Alexion Pharma (ALXN) as FDA Approves Strensiq
October 27, 2015 9:14 AM EDTBaird reiterated an Outperform rating and $221.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following Strensiq's FDA approval for hypophosphatasia. The company plans to use a sales force approximately double that at Soliris launch, to promote both Strensiq and Kanuma (PDUFA: December 8) along with Medical... More
Alexion Pharma (ALXN) to Resume Trading at 4:15 PM ET
October 23, 2015 3:57 PM EDTAlexion Pharma (NASDAQ: ALXN) to Resume Trading at 4:15 PM ET
... MoreFDA Approves Alexion's (ALXN) Strensiq to Treat Perinatal, Infantile and Juvenile-Onset HPP
October 23, 2015 3:40 PM EDT(Updated - October 23, 2015 3:45 PM EDT)
Today, the U.S. Food and Drug Administration approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
HPP is a rare, genetic, progressive, metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to severe disability and life-threatening complications. It is characterized by defective bone mineralization that can lead to rickets and softening of the bones that result in skeletal abnormalities. It can also cause complications such as profound muscle weakness with loss of mobility, seizures, pain, respiratory failure and... More
Alexion Pharma (ALXN) halted with news pending
October 23, 2015 3:38 PM EDTAlexion Pharma (NASDAQ: ALXN) trading halted with news pending.
... More